Stock AMPH AMPHASTAR PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Amphastar Pharmaceuticals, Inc.

Equities

AMPH

US03209R1032

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
42.02 USD +2.21% Intraday chart for Amphastar Pharmaceuticals, Inc. +4.61% -32.06%
Mar. 13 Transcript : Amphastar Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Mar. 08 Amphastar Pharmaceuticals Insider Sold Shares Worth $842,883, According to a Recent SEC Filing MT

Evolution of the average Target Price on Amphastar Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

37247478696f31ce49bd0.dD1_Hiuda_ac3cPsiiINhjlP8OY3mymLSQ8V7HvcQnQ.I3YRSUr1W57Ku5mD6E5mx1gkw9Zu-R3yGjdxtBW2MTgtZFJRW9gso-yv9w~f448590f23f00c061df8d6f56b97207a

Analyst Recommendations on Amphastar Pharmaceuticals, Inc.

JPMorgan Initiates Amphastar Pharmaceuticals With Overweight Rating, Price Target is $60 MT
BofA Securities Initiates Amphastar Pharmaceuticals at Neutral Rating With $63 Price Target MT
Jefferies Reinstates Buy Rating on Amphastar Pharmaceuticals With $70 Price Target MT
Wells Fargo Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $40, Maintains Equal-Weight Rating MT
Piper Sandler Adjusts Amphastar Pharmaceuticals' Price Target to $40 From $43, Keeps Overweight Rating MT
Jefferies Assumes Amphastar Pharmaceuticals at Buy with $36 Price Target MT
Capital One Initiates Amphastar Pharmaceuticals at Overweight Rating With $44 Price Target MT
Northland Adjusts Price Target on Amphastar Pharmaceuticals to $43 From $33, Keeps Outperform Rating MT
Piper Sandler Raises Price Target for Amphastar Pharmaceuticals to $47 From $35, Maintains Overweight Rating MT
Wells Fargo Adjusts Amphastar Pharmaceuticals' Price Target to $32 From $23, Keeps Equalweight Rating MT
Piper Sandler Adjusts Price Target on Amphastar Pharmaceuticals to $35 From $28, Reiterates Overweight Rating MT
Piper Sandler Upgrades Amphastar Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $28 From $21 MT
AMPHASTAR PHARMACEUTICALS : Wells Fargo Adjusts Price Target on Amphastar Pharmaceuticals to $20 From $21, Maintains Equal-Weight Rating MT
AMPHASTAR PHARMACEUTICALS : Wells Fargo Downgrades Amphastar Pharmaceuticals to Equal-Weight From Overweight; Price Target is $21 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
42.02 USD
Average target price
62.6 USD
Spread / Average Target
+48.98%
High Price Target
71 USD
Spread / Highest target
+68.97%
Low Price Target
50 USD
Spread / Lowest Target
+18.99%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Amphastar Pharmaceuticals, Inc.

JPMorgan Chase
BofA Securities
Jefferies & Co.
Wells Fargo Securities
Piper Sandler
Capital One Securities
Northland Securities

Ratings for Amphastar Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AMPH Stock
  4. Consensus Amphastar Pharmaceuticals, Inc.